A simple pan-specific RNN model for predicting HLA-II binding peptides.

Journal: Molecular immunology
PMID:

Abstract

The prediction of human leukocyte antigen (HLA) class II binding peptides plays important roles in understanding the mechanism of immune recognition and developing effective epitope-based vaccines. In this work, gated recurrent unit (GRU)-based recurrent neural network (RNN) was successfully employed to establish a pan-specific prediction model of HLA-II-binding peptides by using only the HLA and peptide sequence information. In comparison with the existing pan-specific models of HLA-II-binding peptides, the GRU-based RNN model covered a broad spectrum of HLA-II molecules including 50 HLA-DR, 47 HLA-DQ, and 19 HLA-DP molecules with peptide lengths varying from 8 to 43 mers. The results demonstrated strong discriminant capabilities of the GRU-based RNN model, of which the AUC values were 0.92, 0.88, and 0.88 for the training, validation, and test sets, respectively. Also, the GRU-based model showed state-of-the-art performances in predicting the binding peptides with the length ranging from 8-32 mers, which provides an efficient method for predicting HLA-II-binding peptides of longer lengths in comparison with the available methods. Overall, taking the advantages of the RNN architecture, the established pan-specific GRU model can be used for predicting accurately the HLA-II-binding peptides in a simple and direct manner.

Authors

  • Yu Heng
    Key Laboratory of Biorheological Science and Technology (Ministry of Education), Chongqing University, Chongqing, 400044, China; College of Bioengineering, Chongqing University, Chongqing, 400044, China.
  • Zuyin Kuang
    Key Laboratory of Biorheological Science and Technology (Ministry of Education), Chongqing University, Chongqing, 400044, China.
  • Wenzhao Xie
    College of Bioengineering, Chongqing University, Chongqing, 400044, China.
  • Haoqi Lan
    College of Bioengineering, Chongqing University, Chongqing, 400044, China.
  • Shuheng Huang
    College of Bioengineering, Chongqing University, Chongqing, 400044, China.
  • Linxin Chen
    College of Bioengineering, Chongqing University, Chongqing, 400044, China.
  • Tingting Shi
    Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, China.
  • Lei Xu
    Key Laboratory of Biomedical Information Engineering of the Ministry of Education, Department of Biomedical Engineering, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China.
  • Xianchao Pan
    Department of Medicinal Chemistry, College of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China. Electronic address: panxc@swmu.edu.cn.
  • Hu Mei
    Key Laboratory of Biorheological Science and Technology (Ministry of Education), Chongqing University, Chongqing, 400044, China; College of Bioengineering, Chongqing University, Chongqing, 400044, China. Electronic address: meihu@cqu.edu.cn.